Clinical Immunology of Thymic Tumors in Patients with Myasthenia Gravis

  • Johan A. Aarli


Approximately 10–15% of all myasthenia gravis (MG) patients have a thymoma, and 30 – 60% of all thymoma cases are associated with MG. The clinical manifestations of MG with thymoma are similar to MG with thymic hyperplasia, but the thymoma patients are usually older, and the male:female ratio is about 1:1 compared with 1:2–3 for thymic hyperplasia. Polymyositis and cardiac involvement are uncommon in non-thymoma cases, but are well known in MG with thymoma (Aarli, 1994).


Ryanodine Receptor Myoid Cell Thymus Hyperplasia Thymic Tumor Neoplastic Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aarli, JA. Myasthenia Gravis and Thymoma. Chapter 10 in: Handbook of Myasthenia Gravis and Myasthenic Syndromes (ed. R. P. Lisak) Marcel Dekker, New York, Pp.207–224, 1994.Google Scholar
  2. Aarli JA, Lefvert AK, Tønder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect hemagglutination. J Neuroimmunol 1981; 1:421–427.PubMedCrossRefGoogle Scholar
  3. Aarli JA, Gilhus NE, Hofstad H. CA-antibody: an immunological marker of thymus neoplasia in myasthenia gravis? Acta Neurol scand. 1987;76:55–57.PubMedCrossRefGoogle Scholar
  4. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990; 82:284–288.PubMedCrossRefGoogle Scholar
  5. Ansevin CF, Agamanolis DP. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol 1996; 53:197–199.PubMedCrossRefGoogle Scholar
  6. Dardenne M, Savino W, Bach JF. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am J Pathol. 1987; 126:194–198.PubMedGoogle Scholar
  7. Gautel M, Lakey A, Barlow PD, Holmes Z, Scales S, Leonard K, Labeit S, Mygland Å, Gilhus NE, Aarli JA. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993; 43:1581–1585.PubMedCrossRefGoogle Scholar
  8. Geld HW van der and Strauss AJL. Autoantibodies and myasthenia gravis: immunological relationship between striated muscle and thymus. Lancet 1966:i:631–637.Google Scholar
  9. Geuder KI, Marx A, Witzemann V, Schalke B, Kirchner T, Müller-Hermelink. Genomic organization and lack of transcription of the nicotinic acetylcholine receptor subunit genes in myasthenia gravis-associated thymoma. Lab Invest 1992; 66:452–458.PubMedGoogle Scholar
  10. Gilhus N. E., Aarli, J. A., Christensson, B., Matre, R.: Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymoma from myasthenia gravis patients. J. Neuroimmunology 1984; 34:55–64.CrossRefGoogle Scholar
  11. Gilhus NE, Aarli JA, Janzen RWC, Otto HF, Fasske E, Matre R. Skeletal muscle antibodies in patients with a thymic tumour but without myasthenia gravis. J Neuroimmunol 1985; 8:69–75.PubMedCrossRefGoogle Scholar
  12. Gilhus NE, Matre R, Aarli JA, Hofstad H, Thunold S. Thymic lymphoepitheliomas and skeletal muscle expressing common antigen(s). Acta neurol scand 1986; 73:428–433.PubMedCrossRefGoogle Scholar
  13. Gilhus NE, Willcox N, Harcourt G, Nagvvekar N, Beeson D, Vincent A, Newsom-Davis J. Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. J Neuroimmunol 1995; 56:65–76.PubMedCrossRefGoogle Scholar
  14. Hara Y, Ueno S, Uemichi T, Takhashi N, Yorifuji S, Fujii Y, Tarui S. Neoplastic epithelial cells express alpha subunit of muscle nicotinic acetylcholine receptor in thymomas from patients with myasthenia gravis. FEBS letters 1991:279:137–140.PubMedCrossRefGoogle Scholar
  15. Hassel B, Gilhus NE, Aarli JA, Skogen OR. Fulminant myasthenia gravis and polymyositis after thymectomy for thymoma. Acta neurol scand 1992; 85:63–65.PubMedCrossRefGoogle Scholar
  16. Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Müller-Hermelink HK. Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am J Pathol 1988; 130:268–280.PubMedGoogle Scholar
  17. Kornstein MJ, Asher O, Fuchs S. Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas. Am J Pathol 1995; 146:1320–1324.PubMedGoogle Scholar
  18. Kuks JBM. The thymus and myasthenia gravis. Drukkerij Regenboog, Groningen 1992.Google Scholar
  19. Kuks JB, Limburg PC, Horst G, Oosterhuis HJ. Antibodies to skeletal muscle in myasthenia gravis. Part 3. Relation with clinical course and therapy. J Neurol Sci 1993; 120:168–173.PubMedCrossRefGoogle Scholar
  20. Marx A, Osborn M, Tzartos S, Geuder KI, Schalke B, Nix W, Kirchner T, Müller-Hermelink HK. A striational muscle antigen and myasthenia gravis-associated thymomas share an acetylcholine-receptor epitope. Dev. Immunol. 1992; 2:77–84.Google Scholar
  21. Matsui M, Wada H, Ohta M, Kuroda Y. Potential role of thymoma and other mediastinal tumors in the pathogenesis of myasthenia gravis. J Neuroimmunol 1993; 44:171–176.PubMedCrossRefGoogle Scholar
  22. Mygland AÅ, Tysnes OB, Aarli JA, Flood PR, Gilhus NE. Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmic reticulum. J Neuroimmunol 1992; 37:l–7.CrossRefGoogle Scholar
  23. Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992; 32:589–591.PubMedCrossRefGoogle Scholar
  24. Mygland Å, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiat 1994; 57:843–846.PubMedCrossRefGoogle Scholar
  25. Mygland Å., Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995; 62:79–83.PubMedCrossRefGoogle Scholar
  26. Osborn M, Marx A, Kirchner T, Tzartos SJ, Plessman U, Weber K. A shared epitope in the acetylcholine receptor alpha subunit and fast troponin I of skeletal muscle. Is it important for myasthenia gravis? Am J Pathol 1992; 140:1215–1223.Google Scholar
  27. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, Van Kempen GTH, Chauplannaz G, Wintzen AR, van Dijk JG, Newsom-Davis J. Acquired neuromyotonia: Evidence of autoantibodies directed against K+−channels of peripheral nerve. Ann Neurol 1995; 38:714–722.PubMedCrossRefGoogle Scholar
  28. Skeie GO, Mygland Å, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: Clinical correlations. Autoimmunity 1995; 20:99–104.PubMedCrossRefGoogle Scholar
  29. Somnier FE. Exacerbation of myasthenia gravis after removal of thymoma. Acta Neurol Scand 1994; 90:56–66.PubMedCrossRefGoogle Scholar
  30. Somnier FE, Trojaburg W. Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol 1993; 89:73–87.PubMedCrossRefGoogle Scholar
  31. Spurkland A, Gilhus NE, Rønningen KS, Aarli JA, Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Ant. 1991; 37:90–93.CrossRefGoogle Scholar
  32. Strauss AJ, Seegal BC, Hsu JC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol (NY) 1960; 195:184–191.CrossRefGoogle Scholar
  33. Weigert C. Patologisch—anatomischhes Beitrag zur Erbschen Krankheit. Neurolog Zentralblatt 1901; 20:594–597.Google Scholar
  34. Wheatley LM, Urso D, Zheng Y, Loh E, Levinson AI. Molecular analysis of intrathymic acetylcholine receptor. Ann NY Acad Sci 1993, 681:74–82.PubMedCrossRefGoogle Scholar
  35. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992; 66:331–336.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Johan A. Aarli
    • 1
  1. 1.Department of NeurologyUniversity ClinicBergenNorway

Personalised recommendations